The Agrochemical Cartel · Investigation · 2013–present
Syngenta's record.
The fourth firm in the cartel — now Chinese state-owned — has one settlement that is history and one lawsuit still being fought. We grade them differently.
FACT
§2 · Thesis
Grade each claim, don't lump them: Viptera is settled fact; the paraquat suits are live, contested allegations.
Syngenta rushed a GM corn trait to market before China would take it, then paid ~$1.5B to farmers. Separately, thousands with Parkinson's are suing over its weedkiller paraquat — unproven, and we say so.
§5 · Graded Claim
Viptera: GM corn sold ahead of China's approval → China rejected U.S. corn → a ~$1.51B settlement.
FACT
Syngenta commercialized its MIR162 trait (Agrisure Viptera, later Duracade) in the U.S. before China approved it for import. From 2013 China rejected U.S. corn containing the trait, prices fell, and farmers sued. In re Syngenta AG MIR 162 Corn Litigation (MDL 2591, D. Kan.) settled for ~$1.51 billion, with final approval in December 2018 — among the largest U.S. agricultural-litigation settlements. Resolved without an admission of liability.
§5 · Graded Claim
Paraquat and Parkinson's: an active MDL, not an adjudicated fact.
SOME SMOKE
Thousands with Parkinson's disease have sued Syngenta (and former distributor Chevron) in In re Paraquat Products Liability Litigation (MDL 3004, S.D. Ill.), alleging its weedkiller paraquat causes the disease and that the company knew and failed to warn, pointing to internal documents. Syngenta denies causation and contests the claims; the regulatory picture is mixed. We grade the existence of the litigation as FACT and the causation/knowledge claims as an unresolved, attributed dispute — not our finding.
The number
$1.51BViptera settlement — among the largest U.S. agricultural-litigation payouts
Syngenta sold its MIR162 corn trait in the U.S. before China would take it; China's rejection from 2013 dropped prices and triggered a wave of farmer suits. In re Syngenta AG MIR 162 Corn Litigation (MDL 2591, D. Kan.) settled for about $1.51 billion, final approval December 2018 — resolved without an admission of liability. This number is settled fact; the separate paraquat suits are not.
In re Syngenta AG MIR 162 Corn Litigation, MDL 2591 (D. Kan.), Dec. 2018
The record
How this page is graded.
- FACT: Syngenta marketed the MIR162 trait before Chinese import approval, and paid ~$1.51 billion to settle the resulting farmer litigation (final approval Dec. 2018).
- NOT asserted: that paraquat is proven to cause Parkinson's, or that a court has found Syngenta liable for concealing a risk — that litigation is ongoing and contested.
- NOT asserted: that the Viptera settlement is an admission of legal wrongdoing — class settlements typically resolve claims without one.
§7 · Why it matters now
Why it matters.
Syngenta completes the quartet the consolidation left standing, and its two marks show why this hub grades each claim instead of lumping them. The Viptera settlement is over, the number fixed, and it is fact. The paraquat suits are live, the science and liability contested, and honesty means calling them allegations even where the documents look damning. That discipline is the difference between an investigation and a pile-on — and it is the bridge into the pesticide immunity playbook, where the industry works to make paraquat plaintiffs fight the same uphill battle Roundup plaintiffs did.
▸ The Agrochemical Cartel →
▦ Ledger gaps
Help us fill these lines.
- OpenThe outcome of the paraquat MDL and whether the causation and failure-to-warn allegations are ever proven.
- OpenThe full internal-document record on what Syngenta knew about paraquat and Parkinson's risk, and when.
- OpenHow the ~$1.51B Viptera settlement was ultimately distributed among the classes of corn producers and exporters.
Help fill these →